Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30421153 | 0.88 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL21768419 | 0.82 | DGAT1 (0.42) | DGAT1NPC1ALOX5APFEN1 | |
| SCHEMBL30805809 | 0.81 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL30805805 | 0.81 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL20767549 | 0.79 | DGAT1 (0.46) | DGAT1NPC1ALOX5APFEN1 | |
| SCHEMBL30421232 | 0.78 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL20455667 | 0.76 | DGAT1 (0.38) | DGAT1NPC1 | |
| SCHEMBL29659291 | 0.76 | DGAT1 (0.38) | DGAT1NPC1 | |
| SCHEMBL31710334 | 0.75 | DGAT1 (0.42) | DGAT1NPC1 | |
| SCHEMBL27193529 | 0.75 | DGAT1 (0.47) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250099481-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2023121713-A1 | BCL-2 INHIBITORS | NEW AVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | DGAT1 3717/4885NPC1 3386/4885ALOX5AP 2053/4885 |
| US-20250099481-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | DGAT1 3806/4885NPC1 3089/4885ALOX5AP 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.